Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 17, 2026
TickeronGET DAILY SIGNALS
Abbott Laboratories (ABT) Delivers Q2 Earnings Beat and Raises Full-Year EPS Outlook

Abbott Laboratories (ABT) Delivers Q2 Earnings Beat and Raises Full-Year EPS Outlook

Key Takeaways

  • Abbott reported Q2 2026 adjusted earnings per share of $1.31, exceeding the consensus estimate of $1.28.
  • Revenue reached $12.59 billion, reflecting year-over-year growth driven by key segments.
  • The company raised its full-year 2026 adjusted EPS outlook while reaffirming sales guidance.
  • Comparable sales grew 4.8% in the quarter.
  • Results highlighted strength in core businesses amid a shifting product mix.
  • Post-earnings investor focus centers on the raised EPS target range of $5.45 to $5.60.

Earnings Context and Why It Matters

Abbott Laboratories operates in the healthcare sector with diversified segments including diagnostics, medical devices, nutrition, and established pharmaceuticals. The second-quarter results provide an update on demand trends, pricing dynamics, and operational execution following the first-quarter report in April 2026. Investors track these updates closely because they influence full-year guidance, margin trends, and capital allocation decisions in a competitive industry environment.

Reported Results

Abbott reported second-quarter 2026 adjusted diluted earnings per share of $1.31, surpassing the consensus estimate of $1.28 by $0.03. Revenue totaled $12.59 billion, up from $11.14 billion in the prior-year period. Comparable sales increased 4.8%. The company raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60 while maintaining its sales outlook. Key operating metrics reflected continued momentum in core product areas, with results generally exceeding analyst expectations on both the top and bottom lines. From what I see, these figures underscore steady execution across the portfolio.

Market Reaction and Investor Sentiment

Shares of ABT moved following the July 16 release, with attention on the earnings beat and the upward revision to full-year EPS guidance. Market participants interpreted the results as a positive signal of business resilience, particularly given the reaffirmed sales target and the raised profitability outlook. Sentiment heading into the report had been constructive, and the actual figures reinforced confidence in the company’s execution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

AI Tools in Portfolio Analysis

In my research process, I frequently rely on Tickeron’s AI-powered tools to dig deeper into company fundamentals and technical signals. AI Screener stands out as a practical resource for filtering stocks by industry, market cap, performance metrics, and AI-driven indicators. It helps surface relevant comparables and pattern-based insights without the need for manual data crunching, allowing me to cross-check earnings momentum against broader sector trends efficiently.

Forward Outlook and Key Factors to Monitor

With the raised EPS guidance now in place, investors will monitor Abbott’s progress toward the updated full-year target range of $5.45 to $5.60. Management commentary emphasized ongoing strength across business segments and a favorable product mix shift.

Upcoming catalysts include third-quarter results expected in October 2026, along with updates on new product launches and regulatory milestones. Cost management, supply chain stability, and demand trends in diagnostics and medical devices remain important areas to watch.

Broader industry dynamics, including reimbursement changes and competitive pressures, could also influence performance. The company’s ability to sustain comparable sales growth while delivering on the revised profitability targets will be a central focus for the remainder of the year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ABT

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ABT in -1.42% downward trend, sliding for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABT declined for three days, in 169 of 298 cases, the price declined further within the following month. The odds of a continued downward trend are 57%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 17 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABT as a result. In 39 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

The Moving Average Convergence Divergence Histogram (MACD) for ABT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 30 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.

ABT moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

ABT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for ABT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 170 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

The Aroon Indicator entered an Uptrend today. In 126 of 258 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.722) is normal, around the industry mean (4.142). P/E Ratio (35.461) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.253). Dividend Yield (0.023) settles around the average of (0.011) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of health care products

Industry MedicalNursingServices

Industry
Medical Specialties
Address
100 Abbott Park Road
Phone
+1 224 667-6100
Employees
115000
Web
https://www.abbott.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.